Characterization_NN of_IN Hepatitis_NP C_NP Virus_NP Quasispecies_NNS by_IN Matrix-Assisted_NP Laser_NP Desorption_NP Ionization-Time_NP of_IN Flight_NP (_( Mass_NP Spectrometry_NP )_) Mutation_NP Detection_NP Hepatitis_NP C_NP virus_NN (_( HCV_NP )_) ,_, the_DT causative_JJ agent_NN of_IN hepatitis_NP C_NP ,_, frequently_RB causes_VBZ chronic_JJ infection_NN ._SENT The_DT mechanisms_NNS of_IN viral_JJ persistence_NN continue_VBP to_TO be_VB the_DT object_NN of_IN investigation_NN ._SENT An_DT important_JJ aspect_NN of_IN HCV_NP chronic_JJ infection_NN is_VBZ the_DT quasispecies_JJ nature_NN of_IN the_DT viral_JJ population_NN ,_, which_WDT has_VBZ been_VBN particularly_RB well_RB documented_VBN in_IN the_DT hypervariable_JJ region_NN 1_CD of_IN the_DT E2_NP glycoprotein_NN ._SENT Recent_JJ studies_NNS show_VBP that_IN characterization_NN of_IN the_DT quasispecies_NNS diversity_NN at_IN the_DT amino_NN acid_NN level_NN can_MD help_VB to_TO predict_VB the_DT outcome_NN of_IN HCV_NP infection_NN ._SENT Currently_RB the_DT accurate_JJ characterization_NN of_IN HCV_NP quasispecies_NNS requires_VBZ the_DT cloning_VBG of_IN PCR_NP products_NNS ,_, followed_VBN by_IN the_DT sequencing_VBG of_IN many_JJ clones_NNS ._SENT In_IN this_DT study_NN we_PP present_VBP a_DT new_JJ method_NN to_TO characterize_VB HCV_NP quasispecies_NNS ,_, based_VBN on_IN in_IN vitro_NN translation_NN of_IN the_DT amplicons_NNS ,_, followed_VBN by_IN mass_JJ spectrometry_NN analysis_NN of_IN the_DT resulting_VBG peptide_NN mix_NN ._SENT The_DT assay_NN was_VBD used_VBN on_IN reference_NN HCV_NP samples_NNS and_CC on_IN clinical_JJ samples_NNS ._SENT In_IN principle_NN ,_, this_DT method_NN could_MD be_VB applied_VBN to_TO other_JJ chronic_JJ viral_JJ infections_NNS in_IN which_WDT quasispecies_NNS play_VBP a_DT role_NN ._SENT The_DT consequences_NNS of_IN hepatitis_NP C_NP virus_NN (_( HCV_NP )_) infection_NN are_VBP well_RB known_VBN and_CC include_VBP chronic_JJ infection_NN in_IN as_RB many_JJ as_IN 85_CD %_NN of_IN cases_NNS ,_, of_IN which_WDT up_RB to_TO 24_CD %_NN will_MD progress_VB to_TO liver_NN cirrhosis_NN ,_, and_CC development_NN of_IN hepatocellular_JJ carcinoma_NN ._SENT Ever_RB since_IN the_DT demonstration_NN of_IN chronic_JJ infections_NNS caused_VBN by_IN HCV_NP ,_, the_DT mechanisms_NNS of_IN viral_JJ persistence_NN have_VBP been_VBN the_DT subject_NN of_IN investigation_NN ._SENT A_DT related_JJ problem_NN is_VBZ the_DT lack_NN of_IN protection_NN against_IN reinfection_NN following_VBG successful_JJ clearance_NN of_IN the_DT primary_JJ infection_NN ,_, in_IN both_DT humans_NNS and_CC chimpanzees_NNS ,_, in_IN spite_NN of_IN the_DT development_NN of_IN both_DT humoral_JJ and_CC cell-mediated_JJ immunity_NN ._SENT The_DT quasispecies_NNS nature_NN of_IN HCV_NP in_IN a_DT given_VBN host_NN ,_, i.e._FW ,_, the_DT presence_NN of_IN several_JJ distinct_JJ ,_, but_CC closely_RB related_VBN mutants_NNS of_IN HCV_NP that_WDT are_VBP constantly_RB changing_VBG due_JJ to_TO the_DT low_JJ fidelity_NN of_IN the_DT RNA_NP polymerase_NN ,_, may_MD contribute_VB to_TO HCV_NP pathogenesis_NN ,_, for_IN example_NN ,_, through_IN generation_NN of_IN immune_JJ escape_NN mutants_NNS ._SENT In_IN this_DT regard_NN ,_, the_DT 31-amino-acid_JJ region_NN at_IN the_DT N_NP terminus_NN of_IN the_DT E2_NP glycoprotein_NN ,_, referred_VBD to_TO as_RB hypervariable_JJ region_NN 1_CD (_( HVR1_NP )_) ,_, has_VBZ been_VBN particularly_RB well_RB studied_VBN ,_, because_IN most_JJS mutations_NNS accumulate_VBP in_IN this_DT domain_NN ._SENT Interestingly_RB ,_, mutations_NNS in_IN HVR1_NP introduced_VBD significant_JJ changes_NNS in_IN its_PP$ predicted_VBN secondary_JJ structure_NN ._SENT In_IN addition_NN ,_, HVR1_NP has_VBZ been_VBN shown_VBN to_TO contain_VB epitopes_NNS for_IN neutralizing_VBG antibodies_NNS ._SENT A_DT convincing_JJ demonstration_NN of_IN the_DT role_NN of_IN quasispecies_JJ diversity_NN of_IN HVR1_NP in_IN HCV_NP pathogenesis_NN was_VBD published_VBN recently_RB by_IN Farci_NP and_CC coworkers_NNS ._SENT In_IN that_DT study_NN it_PP was_VBD shown_VBN that_IN the_DT outcome_NN of_IN HCV_NP infection_NN is_VBZ predicted_VBN by_IN the_DT change_NN in_IN diversity_NN of_IN HVR1_JJ amino_NN acid_NN sequences_NNS at_IN the_DT time_NN of_IN seroconversion_NN ,_, an_DT increase_NN in_IN HVR1_JJ diversity_NN being_VBG associated_VBN with_IN chronicity_NN ._SENT Furthermore_RB ,_, a_DT larger_JJR number_NN of_IN nonsynonymous_JJ mutations_NNS occurring_VBG in_IN HVR1_NP were_VBD documented_VBN in_IN cases_NNS of_IN progressive_JJ hepatitis_NN ._SENT This_DT is_VBZ consistent_JJ with_IN the_DT demonstration_NN that_IN some_DT mutants_NNS in_IN HVR1_NP are_VBP indeed_RB immune_JJ escape_NN mutants_NNS ._SENT The_DT greater_JJR variation_NN in_IN amino_NN acid_NN sequence_NN of_IN the_DT HVR1_NP in_IN the_DT viral_JJ population_NN and_CC the_DT progression_NN of_IN disease_NN are_VBP thought_VBN to_TO reflect_VB the_DT inability_NN of_IN the_DT immune_JJ system_NN to_TO contain_VB viral_JJ variation_NN ._SENT In_IN practice_NN ,_, genetic_JJ changes_NNS in_IN HCV_NP must_MD be_VB demonstrated_VBN by_IN PCR_NP amplification_NN of_IN the_DT HVR1-coding_NP region_NN of_IN the_DT HCV_NP genome_NN from_IN samples_NNS obtained_VBN before_IN and_CC after_IN seroconversion_NN ,_, followed_VBN by_IN cloning_VBG and_CC sequencing_VBG of_IN at_IN least_JJS 10_CD clones_NNS from_IN which_WDT the_DT corresponding_JJ amino_NN acid_NN sequences_NNS are_VBP determined_VBN ._SENT This_DT procedure_NN would_MD entail_VB enormous_JJ logistical_JJ problems_NNS for_IN a_DT clinical_JJ microbiology_NN laboratory_NN ._SENT In_IN order_NN to_TO address_VB this_DT issue_NN ,_, we_PP have_VBP developed_VBN a_DT more-streamlined_JJ mutation_NN detection_NN method_NN for_IN the_DT HVR1_JJ region_NN of_IN HCV_NP that_WDT uses_VBZ matrix-assisted_JJ laser_NN desorption_NN ionization-time_NN of_IN flight_NN (_( MALDI-TOF_NP )_) mass_JJ spectrometric_JJ analysis_NN of_IN in_IN vitro-synthesized_JJ peptides_NNS as_IN previously_RB described_VBN ._SENT Amplicons_NNS are_VBP generated_VBN by_IN reverse_JJ transcription_NN (RT)-PCR_NN using_VBG RNA_NP template_NN extracted_VBN from_IN serum_NN samples_NNS ,_, and_CC these_DT amplicons_NNS are_VBP in_IN turn_NN used_VBN as_IN a_DT template_NN to_TO synthesize_VB tagged_VBN peptides_NNS in_IN a_DT coupled_VBN in_IN vitro_NN transcription-translation_NN reaction_NN ._SENT The_DT tagged_VBN test_NN peptides_NNS are_VBP then_RB purified_VBN using_VBG the_DT tag_NN prior_RB to_TO mass_JJ determination_NN by_IN mass_JJ spectrometry_NN ._SENT Variations_NNS in_IN the_DT nucleic_JJ acid_JJ sequence_NN of_IN the_DT virus_NN translate_VB into_IN mass_JJ shifts_NNS in_IN the_DT encoded_VBN peptides_NNS ._SENT A_DT major_JJ advantage_NN of_IN this_DT method_NN for_IN quasispecies_NNS analysis_NN ,_, in_IN addition_NN to_TO ignoring_VBG silent_JJ mutations_NNS that_WDT cannot_MD affect_VB immunogenicity_NN ,_, is_VBZ that_IN MALDI-TOF_NP mass_NN spectrometry_NN can_MD detect_VB mutant_JJ peptides_NNS present_JJ at_IN a_DT low_JJ frequency_NN in_IN a_DT mixture_NN ,_, which_WDT is_VBZ not_RB possible_JJ by_IN direct_JJ DNA_NN sequencing_VBG of_IN the_DT amplicon_NN ,_, hence_RB the_DT need_NN for_IN the_DT tedious_JJ process_NN of_IN sequencing_VBG multiple_NN cloned_VBN PCR_NP products_NNS HCV_NP strains_NNS and_CC plasmids_NNS ._SENT |_SYM The_DT HCV_NP strain_NN H-77_JJ in_IN the_DT form_NN of_IN a_DT serum_NN aliquot_NN ;_: the_DT HCV_NP infectious_JJ clone_NN pCV-H77C_NN of_IN strain_NN H-77_JJ ,_, genotype_NN 1a_NP ;_: and_CC the_DT infectious_JJ clone_NN pCV-J4L6S_NNS of_IN strain_NN J4_NP ,_, genotype_NN 1b_NN ,_, were_VBD obtained_VBN from_IN R._NP H._NP Purcell_NP and_CC Jens_NP Bukh_NP ,_, Hepatitis_NP Viruses_NP Section_NP ,_, Laboratory_NP of_IN Infectious_NP Diseases_NPS ,_, National_NP Institute_NP of_IN Allergy_NP and_CC Infectious_NP Diseases_NPS ,_, National_NP Institutes_NPS of_IN Health_NP ._SENT Primers_NNS ._SENT |_SYM Primers_NP were_VBD designed_VBN to_TO bracket_VB the_DT segment_NN encoding_VBG the_DT HVR1_NP ,_, targeting_VBG regions_NNS conserved_VBN between_IN the_DT sequences_NNS of_IN pCV-H77C_NN and_CC pCV-J4L6S_NNS ._SENT Primer_NP pairs_NNS were_VBD designed_VBN for_IN performing_VBG nested_VBN PCR_NP ._SENT The_DT outer_JJ pair_NN consisted_VBN of_IN primer_NN HCPEP-1_NP (_( 5'GGTTCTGATTGTGCTGCTACTATTTGC_NP 3_CD '_'' )_) ,_, whose_WP$ sequence_NN is_VBZ homologous_JJ to_TO the_DT end_NN of_IN the_DT region_NN coding_VBG for_IN the_DT C_NP terminus_NN of_IN E1_NP ,_, just_RB ahead_RB of_IN the_DT E1-E2_NP junction_NN ,_, and_CC HCPEP-2_NP (_( 5_CD '_POS CTATTGATGTGCCAACTGCCG_NP 3_CD '_'' )_) ,_, whose_WP$ sequence_NN is_VBZ homologous_JJ to_TO the_DT segment_NN of_IN the_DT E2_NP gene_NN just_RB after_IN the_DT end_NN of_IN the_DT HVR1_JJ coding_VBG segment_NN ._SENT The_DT outer_JJ pair_NN generates_VBZ an_DT amplicon_NN of_IN 161_CD bp_NN ._SENT Several_JJ different_JJ primers_NNS were_VBD used_VBN for_IN the_DT second_JJ round_NN of_IN PCR_NP ._SENT The_DT sense_NN primer_NN HCFLAG-3_NP consisted_VBD of_IN a_DT restriction_NN site_NN upstream_RB of_IN a_DT T7_JJ promoter_NN consensus_NN sequence_NN ;_: filler_NN DNA_NN to_TO allow_VB for_IN ribosomal_JJ scanning_VBG ;_: a_DT Kozak_NP consensus_NN sequence_NN ;_: and_CC a_DT start_NN codon_NN in_IN frame_NN with_IN the_DT segment_NN encoding_VBG for_IN the_DT Flag_NP tag_NN (_( Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys_NP )_) followed_VBD by_IN a_DT segment_NN (_( in_IN frame_NN )_) homologous_JJ to_TO HCV_NP sequence_NN ,_, overlapping_VBG with_IN HCPEP-1_NP ,_, and_CC internal_JJ to_TO it_PP by_IN 3_CD nucleotides_NNS ._SENT The_DT antisense_NN primer_NN HCFLAG-4_NP contained_VBD a_DT stretch_NN of_IN 15_CD Ts_NN to_TO generate_VB a_DT poly(A)_JJ tail_NN during_IN transcription_NN ,_, a_DT stop_NN codon_NN in_IN frame_NN with_IN a_DT segment_NN encoding_VBG the_DT Flag_NP tag_NN and_CC in_IN frame_NN with_IN a_DT segment_NN homologous_JJ to_TO HCV_NP sequence_NN ,_, overlapping_VBG with_IN HCPEP-2_NP and_CC internal_JJ to_TO it_PP by_IN 5_CD nucleotides_NNS ._SENT HCFLAG-3_NP and_CC HCFLAG-4_NP generate_VBP an_DT amplicon_NN of_IN 257_CD bp_NN ._SENT For_IN both_DT HCFLAG-3_NP and_CC HCFLAG-4_NP ,_, versions_NNS of_IN these_DT primers_NNS without_IN the_DT Flag_NP coding_VBG segment_NN were_VBD also_RB synthesized_VBN and_CC used_VBN in_IN some_DT experiments_NNS ._SENT Finally_RB ,_, primer_NN HCFLAGALA_NP is_VBZ a_DT modification_NN of_IN HCFLAG-3_NP ,_, containing_VBG a_DT codon_NN for_IN Ala_NP between_IN the_DT Met_NP codon_NN and_CC the_DT Flag_NP coding_VBG segment_NN ._SENT Synthetic_JJ peptide_NN ._SENT |_SYM The_DT synthetic_JJ peptide_NN MVLLLFAGVDAETHVTGGNAGRTTAGLVGLLTPGAKQNIQLINTNGSWHIDYKDDDDK_NP was_VBD obtained_VBN from_IN the_DT Peptide_NP Synthesis_NP Facility_NP ,_, Advanced_NP Protein_NP Technology_NP Center_NP ,_, Hospital_NP for_IN Sick_NP Children_NP ._SENT The_DT sequence_NN of_IN the_DT peptide_NN corresponds_VBZ to_TO that_DT expected_VBN from_IN the_DT translation_NN of_IN an_DT amplicon_NN obtained_VBN from_IN the_DT infectious_JJ clone_NN pCV-H77C_NN ,_, with_IN primers_NNS encoding_VBG for_IN the_DT Flag_NP tag_NN at_IN the_DT C_NP terminus_NN only_RB ._SENT PCR_NP ._SENT |_SYM When_WRB using_VBG plasmid_NP DNA_NP as_IN a_DT template_NN ,_, PCR_NP with_IN the_DT outer_JJ primer_NN pair_NN was_VBD performed_VBN in_IN a_DT total_JJ volume_NN of_IN 100_CD mul_NN and_CC included_VBD 50_CD pmol_NN of_IN each_DT primer_NN ,_, a_DT 200_CD muM_NN concentration_NN of_IN each_DT deoxynucleoside_NN triphosphate_NN ,_, 2.5_CD mM_NP MgCl2_NP ,_, 0.5_CD mul_NN of_IN AmpliTaq_NP Gold_NP (_( Applied_NP Biosystems_NP Inc._NP ,_, Framingham_NP ,_, Mass._NP )_) ,_, and_CC the_DT buffer_NN supplied_VBN by_IN the_DT manufacturer_NN ._SENT Reactions_NNS were_VBD performed_VBN in_IN thin-walled_JJ PCR_NP tubes_NNS (_( Stratagene_NP )_) ,_, overlaid_VBN with_IN 100_CD mul_NN of_IN mineral_NN oil_NN ,_, in_IN a_DT Robocycler-40_NP thermal_JJ cycler_NN (_( Stratagene_NP )_) with_IN the_DT following_VBG parameters_NNS :_: one_CD cycle_NN consisting_VBG of_IN denaturation_NN at_IN 95C_NN for_IN 10_CD min_NN ,_, annealing_VBG at_IN 50C_NN for_IN 1_CD min_NN ,_, and_CC elongation_NN at_IN 72C_NP for_IN 1_CD min_NN 30_CD s_NNS ,_, followed_VBN by_IN 35_CD cycles_NNS with_IN denaturation_NN at_IN 95C_NN for_IN 1_CD min_NN ,_, annealing_VBG at_IN 50C_NN for_IN 1_CD min_NN ,_, and_CC elongation_NN at_IN 72C_NP for_IN 1_CD min_NN 30_CD s._NP Nested_NP PCR_NP with_IN the_DT inner_JJ pair_NN was_VBD performed_VBN by_IN transferring_VBG 10_CD %_NN of_IN the_DT first_JJ PCR_NP mix_NN into_IN a_DT new_JJ PCR_NP mix_NN prepared_VBD essentially_RB as_RB described_VBN above_IN ,_, except_IN for_IN the_DT use_NN of_IN an_DT inner_JJ pair_NN of_IN primers_NNS and_CC adjustment_NN of_IN the_DT buffer_NN and_CC MgCl2_NP ,_, taking_VBG into_IN account_NN the_DT contributions_NNS from_IN the_DT first_JJ round_NN ._SENT Cycling_NN parameters_NNS were_VBD as_RB described_VBN above_IN ,_, except_IN for_IN the_DT annealing_VBG temperature_NN which_WDT was_VBD changed_VBN to_TO 67C_JJ ._SENT Precautions_NNS against_IN PCR_NP contamination_NN ._SENT |_SYM PCR_NP reagents_NNS were_VBD prepared_VBN before_IN each_DT assay_NN in_IN a_DT master_NN mix_NN that_WDT was_VBD then_RB aliquoted_VBN ._SENT The_DT preparation_NN of_IN the_DT master_NN mix_NN ,_, the_DT extraction_NN of_IN the_DT DNA_NN and_CC addition_NN of_IN the_DT template_NN to_TO the_DT PCR_NP ,_, and_CC the_DT thermal_JJ cycling_NN were_VBD performed_VBN in_IN three_CD different_JJ ,_, well-separated_JJ rooms_NNS ,_, each_DT with_IN their_PP$ dedicated_JJ set_NN of_IN micropipettors_NNS and_CC gowns_NNS ._SENT General_JJ precautions_NNS against_IN contamination_NN ,_, including_VBG systematic_JJ use_NN of_IN aerosol-barrier_NN protected_VBN pipette_NN tips_NNS ,_, frequent_JJ changes_NNS of_IN gloves_NNS ,_, and_CC frequent_JJ decontamination_NN of_IN surfaces_NNS with_IN UV_NP light_NN and_CC sodium_NN hypochlorite_NN ,_, were_VBD strictly_RB adhered_VBN to_TO ._SENT RT-PCR_NP ._SENT |_SYM HCV_NP RNA_NP was_VBD extracted_VBN from_IN H77_JJ serum_NN using_VBG the_DT Trizol_NP reagent_NN (_( Life_NP Technologies_NPS )_) as_RB described_VBD previously_RB ._SENT The_DT RNA_NP pellet_NN was_VBD resuspended_VBN in_IN 10_CD mM_NP dithiothreitol_NN and_CC 5_CD %_NN (_( vol/vol_NN )_) RNasin_NP (_( 20_CD to_TO 40_CD U/mul_NN ;_: Promega_NP )_) in_IN nuclease-free_JJ ,_, double-distilled_JJ water_NN (_( ddH2O_NN )_) ._SENT The_DT RNA_NP pellet_NN was_VBD heated_VBN at_IN 65C_JJ for_IN 2_CD min_NN and_CC put_VB on_IN ice_NN ;_: 10.5_CD mul_NN of_IN an_DT RT_NP mix_NN consisting_VBG of_IN 0.5_CD mul_NN of_IN RNasin_NP ,_, 2_CD mul_NN of_IN 10x_NP PCR_NP buffer_NN ,_, 2_CD mul_NN of_IN 25_CD mM_NP MgCl2_NP ,_, 2_CD mul_NN of_IN deoxynucleoside_NN triphosphate_NN (_( 10_CD mM_NP each_DT )_) ,_, 3_CD mul_NN of_IN 10_CD muM_NN HCPEP-2_JJ primer_NN ,_, and_CC 1_CD mul_NN of_IN avian_JJ myeloblastosis_NN virus_NN reverse_NN transcriptase_NN (_( 5_CD to_TO 10_CD U/mul_NP ,_, Promega_NP )_) ._SENT The_DT reaction_NN mixture_NN was_VBD incubated_VBN at_IN 42C_JJ for_IN 1_CD h_NN and_CC then_RB added_VBD in_IN totality_NN to_TO a_DT PCR_NP mix_NN consisting_VBG of_IN 8_CD mul_NN of_IN 10x_NP PCR_NP buffer_NN ,_, 8_CD mul_NN of_IN 25_CD mM_NP MgCl2_NP ,_, 5_CD mul_NN of_IN each_DT primer_JJR stock_NN solution_NN (_( 10_CD muM_NN )_) from_IN the_DT outer_JJ pair_NN ,_, 0.5_CD mul_NN of_IN AmpliTaq_NP Gold_NP ,_, and_CC 53.5_CD mul_NN of_IN ddH2O_NN ._SENT Nested_VBN PCR_NP was_VBD then_RB set_VBN up_RP and_CC performed_VBD as_RB described_VBN above_IN ._SENT In_IN vitro_NN translation_NN ._SENT |_SYM In_IN vitro_NN translation_NN was_VBD performed_VBN in_IN a_DT reticulocyte_NN lysate_NN system_NN by_IN transferring_VBG 7_CD mul_NN of_IN the_DT second-round_JJ PCR_NP mixture_NN to_TO 40_CD mul_NN of_IN master_NN mix_NN of_IN the_DT TNT_NP T7-Quick_NP for_IN PCR_NP DNA_NP (_( Promega_NP )_) ,_, to_TO which_WDT were_VBD added_VBN 1_CD mul_NN of_IN 1_CD mM_NP methionine_NN and_CC 2_CD mul_NN of_IN ddH2O_NN ,_, and_CC incubating_VBG the_DT reaction_NN at_IN 30C_JJ ._SENT Incubation_NN times_NNS of_IN 10_CD ,_, 30_CD ,_, 60_CD ,_, and_CC 90_CD min_NN were_VBD studied_VBN ._SENT Magnetic_JJ bead_NN preparation_NN ._SENT |_SYM Biotinylated_JJ anti-Flag_NN antibody_NN M2_NP (_( Sigma_NP )_) was_VBD bound_VBN to_TO magnetic_JJ beads_NNS coated_VBN with_IN streptavidin_NP (_( Dynabeads_NP M-280_NP ;_: Dynal_NP )_) ,_, following_VBG manufacturer_NN 's_POS recommendations_NNS ,_, by_IN mixing_VBG 2.4_CD mg_NN of_IN magnetic_JJ beads_NNS with_IN 0.1_CD mg_NN of_IN antibody_NN ._SENT The_DT magnetic_JJ bead-antibody_NN preparation_NN was_VBD resuspended_VBN in_IN 200_CD mul_NN of_IN phosphate-buffered_JJ saline_NN with_IN 0.1_CD %_NN bovine_JJ serum_NN albumin_NN and_CC kept_VBN at_IN 4C_JJ ._SENT Peptide_NN purification_NN ._SENT |_SYM Peptide_NP purification_NN was_VBD performed_VBN by_IN adding_VBG 10_CD mul_NN of_IN the_DT magnetic_JJ bead-antibody_NN preparation_NN to_TO the_DT in_IN vitro-translation_NN reaction_NN and_CC incubating_VBG 10_CD min_NN at_IN room_NN temperature_NN ._SENT The_DT beads_NNS were_VBD then_RB separated_VBN with_IN a_DT magnet_NN ,_, washed_VBD 3_CD times_NNS with_IN ammonium_NN bicarbonate_NN 25_CD mM_NNS and_CC three_CD times_NNS with_IN ddH2O_NN ._SENT Finally_RB ,_, beads_NNS were_VBD resuspended_VBN in_IN 20_CD mul_NN of_IN 0.1_CD %_NN trifluoroacetic_JJ acid_NN to_TO elute_VB the_DT bound_JJ peptides_NNS and_CC then_RB were_VBD removed_VBN with_IN a_DT magnet_NN ._SENT The_DT eluted_VBN peptides_NNS were_VBD recovered_VBN in_IN a_DT microcentrifuge_NN tube_NN and_CC lyophilized_VBN in_IN a_DT vacuum_NN centrifuge_NN (_( Speed-Vac_NP )_) ._SENT The_DT purified_VBN peptide_NN were_VBD then_RB resuspended_VBN in_IN 3_CD mul_NN of_IN an_DT alpha-cyano-4-hydroxycinnamic_JJ acid-saturated_JJ solution_NN in_IN 50_CD %_NN acetonitrile_NN and_CC 0.1_CD %_NN trifluoroacetic_JJ acid_NN ,_, prior_RB to_TO MALDI-TOF_NP analysis_NN ._SENT MALDI-TOF_NP mass_NN spectrometry_NN ._SENT |_SYM Mass_NP spectrometry_NN was_VBD performed_VBN at_IN the_DT Mass_NP Spectrometry_NP Laboratory_NP ,_, MMRC_NP ,_, Faculty_NP of_IN Medicine_NP ,_, University_NP of_IN Toronto_NP ._SENT MALDI-TOF_NP mass_JJ spectrometry_NN analyses_NNS were_VBD carried_VBN out_RP by_IN using_VBG an_DT Applied_NP Biosystems_NP Voyager-DE_NP STR_NP mass_NN spectrometer_NN (_( Applied_NP Biosystems_NP Inc._NP )_) ,_, equipped_VBN with_IN a_DT pulsed_VBN UV_NP nitrogen_NN laser_NN (_( wavelength_NN ,_, 337_CD nm_NN ;_: 3-ns_JJ pulse_NN )_) and_CC a_DT dual_JJ microchannel_NN plate_NN detector_NN ._SENT For_IN protein_NN molecular_JJ weight_NN determination_NN ,_, mass_JJ spectra_NN were_VBD acquired_VBN in_IN linear-DE_JJ mode_NN ,_, acceleration_NN voltage_NN was_VBD set_VBN to_TO 20_CD kV_NN ,_, grid_NN voltage_NN was_VBD set_VBN at_IN 94_CD %_NN of_IN the_DT acceleration_NN voltage_NN ,_, guide_NN wire_NN voltage_NN was_VBD set_VBN at_IN 0.050_CD %_NN ,_, delay_NN time_NN was_VBD set_VBN at_IN 175_CD ns_NNS ,_, and_CC the_DT low_JJ mass_NN gate_NN was_VBD set_VBN at_IN 1,000_CD Da_NP ._SENT The_DT protonated_JJ ions_NNS of_IN a_DT mixture_NN of_IN peptides_NNS (_( molecular_JJ mass_NN ,_, 1,294.69_CD to_TO 5,734.59_CD Da_NP )_) were_VBD used_VBN for_IN external_JJ calibration_NN ._SENT For_IN sample_NN analysis_NN ,_, 1.5_CD mul_NN of_IN sample_NN solution_NN was_VBD applied_VBN on_IN the_DT MALDI_NP sample_NN plate_NN ._SENT Mass_NP spectra_NN were_VBD recorded_VBN after_IN evaporation_NN of_IN the_DT solvent_JJ and_CC processed_JJ using_VBG Data_NP Explorer_NP software_NN for_IN data_NN collection_NN and_CC analysis_NN ._SENT Genotyping_NP of_IN HCV_NP from_IN clinical_JJ samples_NNS ._SENT |_SYM RNA_NP was_VBD extracted_VBN from_IN serum_NN samples_NNS as_RB described_VBD above_IN ._SENT A_DT segment_NN of_IN the_DT HCV_NP genome_NN at_IN the_DT Core-E1_NP junction_NN was_VBD amplified_VBN by_IN nested_VBN RT-PCR_NP with_IN the_DT primer_NN pairs_VBZ 493S_H77-978R_H77_JJ and_CC 502S_H77-975R_H77_JJ as_RB described_VBN previously_RB ._SENT The_DT amplicon_NN was_VBD sequenced_VBN using_VBG the_DT primer_NN 502S_H77_JJ as_IN the_DT sequencing_VBG primer_NN ._SENT This_DT was_VBD performed_VBN by_IN the_DT DNA_NP Sequencing_NP Facility_NP ,_, Center_NP for_IN Applied_NP Genomics_NP ,_, Hospital_NP for_IN Sick_NP Children_NP ._SENT The_DT genotype_NN was_VBD then_RB determined_VBN by_IN phylogenetic_JJ analysis_NN ,_, comparing_VBG the_DT sequence_NN with_IN that_IN of_IN reference_NN strains_NNS ._SENT This_DT was_VBD performed_VBN using_VBG the_DT Clustal_NP X_NP for_IN Windows_NP (_( version_NN 1.18_CD )_) program_NN and_CC the_DT Treeview_NP for_IN Windows_NP (_( version_NN 1.5.2_CD )_) program_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Some_RB of_IN the_DT primers_NNS used_VBN to_TO generate_VB amplicons_NNS suitable_JJ for_IN in_IN vitro_NN translation_NN ._SENT Some_DT of_IN the_DT primers_NNS used_VBN to_TO generate_VB amplicons_NNS suitable_JJ for_IN in_IN vitro_NN translation_NN ._SENT Primer_NP HCFLAG-3_NP is_VBZ a_DT sense_NN primer_NN containing_VBG an_DT EcoRI_NP restriction_NN site_NN upstream_RB of_IN a_DT T7_JJ promoter_NN core_NN sequence_NN ,_, followed_VBN by_IN filler_NN DNA_NN (_( including_VBG three_CD Gs_NNS immediately_RB after_IN the_DT T7_JJ core_NN sequence_NN )_) to_TO allow_VB for_IN ribosomal_JJ scanning_VBG ,_, a_DT Kozak_NP consensus_NN sequence_NN ,_, a_DT Flag_NP tag_NN (_( DYKDDDDK_NP )_) coding_VBG region_NN ,_, and_CC a_DT region_NN homologous_JJ to_TO HCV_NP sequence_NN ,_, in_IN frame_NN with_IN the_DT Flag_NP coding_VBG region_NN ._SENT Primer_NP HCFLAG-4_NP is_VBZ an_DT antisense_NN primer_NN containing_VBG a_DT stretch_NN of_IN 15_CD Ts_NN to_TO generate_VB a_DT poly(A)_JJ tail_NN at_IN the_DT time_NN of_IN transcription_NN ,_, a_DT stop_NN codon_NN in_IN frame_NN with_IN a_DT Flag_NP coding_VBG region_NN ,_, and_CC a_DT region_NN homologous_JJ to_TO HCV_NP sequence_NN ._SENT Primer_NP HCFLAGALA_NP is_VBZ a_DT modified_JJ HCFLAG-3_NN with_IN an_DT additional_JJ codon_NN encoding_VBG for_IN alanine_NN ._SENT Peptide_NN purification_NN and_CC MALDI-TOF_NP analysis_NN ._SENT |_SYM Our_JJ initial_JJ design_NN was_VBD to_TO have_VB peptides_NNS synthesized_VBN with_IN the_DT Flag_NP tag_NN at_IN the_DT C_NP termini_NNS ,_, unlike_IN the_DT earlier_JJR work_NN done_VBN on_IN tagged_VBN ,_, in_IN vitro-synthesized_JJ peptides_NNS that_WDT used_VBD an_DT amino-terminal_JJ tag_NN ._SENT A_DT C-terminal_NP tag_NN was_VBD used_VBN to_TO avoid_VB the_DT possibility_NN of_IN purifying_VBG peptides_NNS synthesized_VBN from_IN mRNA_NN that_WDT is_VBZ not_RB full_JJ length_NN ._SENT The_DT disadvantage_NN of_IN this_DT approach_NN is_VBZ that_IN C-terminally_NP tagged_VBD peptides_NNS cannot_MD be_VB used_VBN to_TO detect_VB mutations_NNS that_WDT result_VBP in_IN premature_JJ truncation_NN of_IN the_DT peptide_NN ._SENT However_RB ,_, the_DT HCV_NP genome_NN has_VBZ a_DT single_JJ large_JJ open_JJ reading_NN frame_NN that_WDT encodes_VBZ a_DT polyprotein_NN ,_, and_CC any_DT premature_JJ truncation_NN would_MD generate_VB a_DT replication-defective_JJ virus_NN ._SENT The_DT present_JJ assay_NN is_VBZ designed_VBN to_TO detect_VB mutations_NNS resulting_VBG in_IN amino_NN acid_NN substitutions_NNS ;_: thus_RB ,_, a_DT C-terminal_JJ tag_NN is_VBZ acceptable_JJ ._SENT To_TO test_VB our_PP$ purification_NN method_NN ,_, a_DT synthetic_JJ peptide_NN with_IN a_DT predicted_VBN mass_NN of_IN 6,125_CD Da_NP was_VBD made_VBN whose_WP$ sequence_NN was_VBD derived_VBN from_IN residues_NNS of_IN the_DT pCV-H77C_NN infectious_JJ clone_NN fused_VBN to_TO a_DT C-terminal_NP Flag_NP tag_NN ._SENT After_IN mixing_VBG either_DT 100_CD or_CC 10_CD pmol_NN of_IN the_DT peptide_NN in_IN either_DT phosphate-buffered_JJ saline_NN or_CC TNT-T7_JJ Quick_NP master_NN mix_NN ,_, we_PP could_MD detect_VB the_DT peptide_NN by_IN mass_JJ spectrometry_NN following_VBG magnetic_JJ bead_NN purification_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Even_RB after_IN incubation_NN for_IN 90_CD min_NN at_IN 30C_JJ in_IN the_DT TNT_NP mix_NN ,_, the_DT peptide_NN could_MD still_RB be_VB recovered_VBN ;_: no_DT cleavage_NN products_NNS were_VBD observed_VBN ._SENT Optimization_NN of_IN in_IN vitro_NN transcription-translation_NN ._SENT |_SYM We_PP used_VBD a_DT PCR_NP product_NN obtained_VBN from_IN the_DT pCV-H77C_NN infectious_JJ clone_NN that_WDT should_MD generate_VB the_DT same_JJ peptide_NN as_IN the_DT synthetic_JJ peptide_NN described_VBN above_IN ._SENT We_PP were_VBD unable_JJ to_TO recover_VB a_DT peptide_NN with_IN the_DT expected_VBN mass_NN of_IN 6,125_CD Da_NP ,_, although_IN a_DT peptide_NN of_IN approximately_RB 2,394_CD Da_NP was_VBD consistently_RB recovered_VBN in_IN these_DT experiments_NNS that_WDT was_VBD not_RB present_JJ in_IN negative_JJ controls_NNS lacking_VBG template_NN ._SENT This_DT was_VBD interpreted_VBN to_TO be_VB the_DT result_NN of_IN a_DT cleavage_NN sustained_VBN by_IN the_DT nascent_JJ peptide_NN to_TO generate_VB the_DT Flag_NP tagged_VBD C-terminal_JJ fragment_NN IQLINTNGSWHIDYKDDDDK_NN ,_, which_WDT has_VBZ a_DT predicted_VBN mass_NN of_IN 2,391_CD Da_NP ._SENT Experiments_NNS with_IN primers_NNS designed_VBN to_TO yield_VB a_DT peptide_NN with_IN a_DT Flag_NP tag_NN at_IN the_DT N_NP terminus_NN were_VBD even_RB less_RBR successful_JJ in_IN that_IN we_PP could_MD not_RB retrieve_VB any_DT peptides_NNS ._SENT However_RB ,_, when_WRB using_VBG the_DT primer_NN pair_NN HCFLAG-3_NP and_CC HCFLAG-4_NP ,_, designed_VBN to_TO yield_VB a_DT peptide_NN with_IN the_DT Flag_NP tag_NN at_IN both_DT termini_NNS ,_, we_PP consistently_RB recovered_VBD a_DT peptide_NN of_IN approximately_RB 7,162_CD Da_NP ._SENT We_PP found_VBD no_DT improved_VBN yield_NN by_IN incubating_VBG longer_JJR than_IN 10_CD min_NN ._SENT The_DT mass_NN observed_VBD was_VBD approximately_RB 42_CD Da_NP more_JJR than_IN the_DT 7,120_CD Da_NP predicted_VBD from_IN the_DT pCV-H77C_NN sequence_NN ,_, the_DT two_CD Flag_NP tags_NNS ,_, and_CC the_DT amino-terminal_JJ methionine_NN ._SENT The_DT precision_NN of_IN the_DT mass_JJ spectrometer_NN used_VBN in_IN these_DT experiments_NNS was_VBD expected_VBN to_TO be_VB within_IN 0.1_CD %_NN ._SENT This_DT difference_NN of_IN 42_CD Da_NP would_MD be_VB well_RB accounted_VBN for_IN by_IN the_DT expected_VBN N-terminal_JJ acetylation_NN of_IN the_DT peptide_NN ._SENT Using_VBG these_DT primers_NNS ,_, we_PP could_MD also_RB obtain_VB a_DT peptide_NN of_IN the_DT expected_VBN mass_NN (_( including_VBG acetylation_NN )_) with_IN an_DT amplicon_NN obtained_VBN from_IN the_DT pCV-J4L6S_NNS plasmid_NN (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN several_JJ of_IN these_DT experiments_NNS ,_, a_DT second_JJ peak_NN approximately_RB 16_CD Da_NP apart_RB from_IN the_DT first_JJ peak_NN was_VBD observed_JJ ,_, corresponding_JJ ,_, in_IN all_DT likelihood_NN ,_, to_TO oxidized_VBN methionine_NN ._SENT The_DT 5_CD '_POS primer_NN HCFLAGALA_NP was_VBD then_RB used_VBN to_TO replace_VB HCFLAG-3_NP ,_, and_CC was_VBD designed_VBN so_RB that_IN the_DT synthesized_VBN peptide_NN would_MD begin_VB by_IN the_DT sequence_NN Met-Ala_NP ,_, ensuring_VBG the_DT posttranslational_JJ cleavage_NN of_IN methionine_NN and_CC the_DT acetylation_NN of_IN the_DT residual_JJ peptide_NN ._SENT Experiments_NNS with_IN amplicons_NNS obtained_VBN with_IN this_DT primer_NN from_IN the_DT pCV-H77C_NN plasmid_NN confirmed_VBD this_DT hypothesis_NN :_: we_PP consistently_RB recovered_VBD peptides_NNS with_IN a_DT mass_NN of_IN approximately_RB 7,102_CD Da_NP which_WDT is_VBZ the_DT mass_NN predicted_VBD from_IN the_DT amino_NN acid_NN sequence_NN encoded_VBN by_IN the_DT amplicons_NNS ,_, followed_VBN by_IN methionine_NN cleavage_NN and_CC acetylation_NN ._SENT In_IN contrast_NN to_TO the_DT experiments_NNS presented_VBN above_IN ,_, however_RB ,_, we_PP obtained_VBD our_PP$ best_JJS results_NNS after_IN an_DT incubation_NN of_IN 60_CD min_NN at_IN 30C_JJ ,_, suggesting_VBG that_IN methionine_NN cleavage_NN ,_, which_WDT occurs_VBZ before_IN completion_NN of_IN the_DT nascent_JJ peptide_NN ,_, delayed_VBD the_DT peptide_NN synthesis_NN ._SENT In_IN agreement_NN with_IN our_PP$ hypothesis_NN concerning_VBG N-terminal_JJ methionine_NN oxidation_NN ,_, the_DT extra_JJ peak_NN having_VBG an_DT additional_JJ 16_CD Da_NP was_VBD no_RB longer_RBR observed_JJ when_WRB alanine_NN was_VBD used_VBN to_TO program_VB the_DT removal_NN of_IN the_DT N-terminal_JJ methionine_NN ._SENT MALDI-TOF_NP analysis_NN of_IN reference_NN HCV_NP reagents_NNS ._SENT |_SYM In_IN addition_NN to_TO the_DT MALDI-TOF_NP analysis_NN of_IN clone_NN pCV-H77C_NN we_PP also_RB used_VBD our_PP$ procedure_NN with_IN the_DT clone_NN pCV-J4L6S_NNS ._SENT We_PP consistently_RB obtained_VBD peptides_NNS of_IN the_DT predicted_VBN mass_NN of_IN approximately_RB 7,206_CD Da_NP ._SENT Next_RB ,_, we_PP subjected_VBD to_TO transcription-translation_NN and_CC mass_JJ spectrometry_NN a_DT mix_NN of_IN amplicons_NNS obtained_VBN from_IN the_DT two_CD infectious_JJ clones_NNS ,_, and_CC we_PP consistently_RB obtained_VBD peptide_NN mixtures_NNS of_IN the_DT two_CD expected_VBN masses_NNS ._SENT Lastly_RB ,_, we_PP performed_VBD RT-PCR_NP on_IN HCV_NP RNA_NP from_IN the_DT H-77_JJ serum_NN aliquot_NN ,_, whose_WP$ quasispecies_NNS population_NN has_VBZ been_VBN extremely_RB well_RB characterized_VBN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, we_PP could_MD clearly_RB demonstrate_VB three_CD peptides_NNS species_NNS with_IN observed_JJ masses_NNS of_IN 7,052_CD ,_, 7,105_CD ,_, and_CC 7,126_CD Da_NP ,_, respectively_RB ._SENT MALDI-TOF_NP analysis_NN of_IN clinical_JJ samples_NNS ._SENT |_SYM Results_NNS obtained_VBN from_IN clinical_JJ samples_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT The_DT first_JJ patient_NN presented_VBN at_IN our_PP$ institution_NN at_IN 26_CD months_NNS of_IN age_NN ;_: this_DT male_JJ patient_NN was_VBD referred_VBN for_IN known_VBN hepatitis_NP C_NP infection_NN ._SENT His_PP$ mother_NN was_VBD also_RB suffering_VBG from_IN chronic_JJ hepatitis_NP C._NP The_DT patient_NN was_VBD asymptomatic_JJ ,_, and_CC his_PP$ physical_JJ exam_NN was_VBD unremarkable_JJ ._SENT Laboratory_NP analysis_NN revealed_VBD an_DT elevated_JJ serum_NN alanine_NN aminotransferase_NN (_( ALT_JJ )_) level_NN at_IN 111_CD U/liter_NN (_( normal_JJ ,_, 0_CD to_TO 40_CD U/liter_NN )_) ._SENT Repeat_VB clinical_JJ examination_NN 6_CD months_NNS later_RBR revealed_VBD no_DT changes_NNS ,_, but_CC the_DT ALT_JJ level_NN was_VBD within_IN normal_JJ values_NNS ,_, at_IN 26_CD U/liter_NN ._SENT This_DT patient_NN was_VBD infected_VBN with_IN HCV_NP genotype_NN 1b_NN ._SENT MALDI-TOF_NP analysis_NN on_IN the_DT initial_JJ serum_NN sample_NN demonstrated_VBD the_DT presence_NN of_IN two_CD main_JJ variants_NNS in_IN the_DT HCV_NP quasispecies_NNS ._SENT Remarkably_RB ,_, 6_CD months_NNS later_RBR these_DT had_VBD disappeared_VBN and_CC were_VBD replaced_VBN by_IN new_JJ variants_NNS ._SENT The_DT second_JJ patient_NN was_VBD 21_CD months_NNS old_JJ at_IN presentation_NN in_IN our_PP$ institution_NN ._SENT This_DT female_JJ patient_NN was_VBD referred_VBN for_IN possible_JJ mother-to-infant_JJ transmission_NN of_IN HCV_NP ._SENT She_PP had_VBD been_VBN asymptomatic_JJ and_CC her_PP$ physical_JJ exam_NN was_VBD unremarkable_JJ ._SENT However_RB ,_, her_PP$ laboratory_NN analysis_NN revealed_VBD a_DT serum_NN ALT_NN level_NN of_IN 244_CD U/liter_NN ._SENT Six_CD months_NNS later_RBR ,_, the_DT clinical_JJ examination_NN remained_VBD unchanged_JJ ,_, the_DT ALT_JJ level_NN remained_VBD elevated_JJ at_IN 205_CD U/liter_NN ._SENT A_DT percutaneous_JJ liver_NN biopsy_NN performed_VBN at_IN the_DT time_NN revealed_VBD normal_JJ liver_NN architecture_NN ,_, no_DT fibrosis_NN ,_, but_CC some_DT evidence_NN of_IN inflammation_NN limited_VBN to_TO focal_JJ collections_NNS of_IN inflammatory_JJ cells_NNS in_IN the_DT sinusoids_NNS with_IN scattered_JJ hepatocyte_NN necrosis_NN ._SENT This_DT patient_NN was_VBD infected_VBN with_IN HCV_NP genotype_NN 1a_NP ._SENT MALDI-TOF_NP analysis_NN on_IN the_DT initial_JJ sample_NN showed_VBD a_DT very_RB homogeneous_JJ population_NN ,_, with_IN only_RB a_DT single_JJ HCV_NP variant_NN demonstrated_VBD ._SENT Six_CD months_NNS later_RBR ,_, the_DT HCV_NP quasispecies_NNS had_VBD not_RB changed_VBN ._SENT FIG._NN 2_CD ._SENT |_SYM Mass_NP spectrometry_NN analysis_NN of_IN peptides_NNS obtained_VBN by_IN translation_NN of_IN an_DT amplicon_NN obtained_VBN from_IN clone_NN pCV-H77C_NN with_IN primers_NNS HCFLAG-3_NP and_CC HCFLAG-4_NP ._SENT Mass_NP spectrometry_NN analysis_NN of_IN peptides_NNS obtained_VBN by_IN translation_NN of_IN an_DT amplicon_NN obtained_VBN from_IN clone_NN pCV-H77C_NN with_IN primers_NNS HCFLAG-3_NP and_CC HCFLAG-4_NP ._SENT Based_VBN on_IN the_DT sequence_NN of_IN pCV-H77C_NN ,_, the_DT predicted_VBN mass_NN of_IN the_DT resulting_VBG N-terminal_JJ acetylated_VBN peptide_NN should_MD be_VB 7,162_CD Da_NP ._SENT In_IN several_JJ experiments_NNS ,_, as_RB illustrated_VBN here_RB ,_, a_DT second_JJ peak_NN approximately_RB 16_CD Da_NP apart_RB was_VBD observed_VBN and_CC was_VBD interpreted_VBN as_IN resulting_VBG from_IN oxidation_NN of_IN methionine_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Mass_NP spectrometry_NN analysis_NN of_IN peptides_NNS translated_VBN from_IN amplicons_NNS obtained_VBN with_IN primers_NNS HCFLAGALA_NP and_CC HCFLAG-4_NP ._SENT Mass_NP spectrometry_NN analysis_NN of_IN peptides_NNS translated_VBN from_IN amplicons_NNS obtained_VBN with_IN primers_NNS HCFLAGALA_NP and_CC HCFLAG-4_NP ._SENT (_( A_NP )_) Peptide_NP obtained_VBN from_IN template_NN pCV-H77C_NN ._SENT The_DT predicted_VBN mass_NN of_IN the_DT peptide_NN ,_, after_IN methionine_NN cleavage_NN and_CC N-terminal_JJ acetylation_NN ,_, is_VBZ 7,102_CD Da_NP ._SENT (_( B_NP )_) Peptide_NP obtained_VBN from_IN template_NN pCV-J4L6S_NNS ._SENT The_DT predicted_VBN mass_NN ,_, after_IN methionine_NN cleavage_NN and_CC N-terminal_JJ acetylation_NN ,_, is_VBZ 7,206_CD Da_NP ._SENT (_( C_NP )_) Peptides_NP obtained_VBN from_IN mixing_VBG the_DT amplicons_NNS of_IN pCV-H77C_NN and_CC pCV-J4L6S_NNS ._SENT (_( D_NP )_) Peptides_NP obtained_VBN from_IN the_DT H-77_JJ serum_NN aliquot_NN ._SENT FIG._NN 4_CD ._SENT |_SYM Mass_NP spectrometry_NN analysis_NN of_IN clinical_JJ samples_NNS from_IN patients_NNS with_IN hepatitis_NP C._NP Mass_NP spectrometry_NN analysis_NN of_IN clinical_JJ samples_NNS from_IN patients_NNS with_IN hepatitis_NP C._NP (_( A_NP and_CC B_NP )_) These_DT two_CD samples_NNS were_VBD taken_VBN 6_CD months_NNS apart_RB from_IN a_DT patient_NN infected_VBN with_IN an_DT HCV_NP strain_NN of_IN genotype_NN 1b_NN ._SENT A_DT complete_JJ change_NN of_IN the_DT HCV_NP population_NN was_VBD observed_VBN during_IN that_DT period_NN ._SENT (_( C_NP and_CC D_NP )_) These_DT two_CD samples_NNS were_VBD taken_VBN 6_CD months_NNS apart_RB from_IN a_DT patient_NN infected_VBN with_IN an_DT HCV_NP strain_NN of_IN genotype_NN 1a_NP ._SENT No_DT changes_NNS in_IN the_DT HCV_NP population_NN could_MD be_VB observed_VBN ._SENT In_IN this_DT study_NN we_PP have_VBP developed_VBN a_DT procedure_NN to_TO evaluate_VB the_DT HVR1_JJ peptide_NN diversity_NN in_IN the_DT HCV_NP population_NN of_IN a_DT patient_NN 's_POS serum_NN sample_NN ,_, without_IN the_DT need_NN of_IN cloning_VBG and_CC sequencing_VBG of_IN many_JJ clones_NNS ._SENT This_DT is_VBZ a_DT conceptually_RB straightforward_JJ application_NN of_IN mutation_NN detection_NN using_VBG MALDI-TOF_NP ,_, but_CC several_JJ problems_NNS specific_JJ to_TO HCV_NP HVR1_NP had_VBD to_TO be_VB addressed_VBN ,_, some_DT of_IN which_WDT were_VBD unexpected_JJ ._SENT The_DT power_NN of_IN MALDI-TOF_NP to_TO detect_VB mutations_NNS relies_VBZ on_IN the_DT changes_NNS in_IN mass_NN caused_VBN by_IN amino_NN acid_NN substitutions_NNS ._SENT Single-amino-acid_JJ substitutions_NNS produce_VBP mass_JJ alterations_NNS ranging_VBG from_IN 0_CD to_TO 186_CD Da_NP ._SENT If_IN the_DT peptide_NN is_VBZ short_RB enough_RB ,_, most_JJS of_IN these_DT changes_NNS can_MD be_VB detected_VBN :_: for_IN example_NN in_IN a_DT 10-kDa_NP peptide_NN ,_, all_RB but_CC 14_CD of_IN 380_CD possible_JJ amino_NN acid_NN substitutions_NNS should_MD be_VB detectable_JJ with_IN a_DT mass_JJ accuracy_NN of_IN 200_CD ppm_NN ._SENT However_RB ,_, the_DT effective_JJ mass_NN range_NN of_IN the_DT MALDI_NP instrument_NN imposes_VBZ constraints_NNS on_IN the_DT size_NN of_IN the_DT HVR1_NP test_NN sequence_NN that_WDT is_VBZ to_TO be_VB translated_VBN to_TO roughly_RB 150_CD bp_NN ._SENT Unfortunately_RB ,_, sequence_NN comparison_NN between_IN all_DT HCV_NP genotypes_NNS failed_VBD to_TO reveal_VB conserved_VBN sequence_NN across_IN all_DT genotypes_NNS within_IN such_PDT a_DT short_JJ region_NN around_IN the_DT HVR1_NP that_WDT could_MD be_VB used_VBN as_IN primer_JJR binding_JJ sites_NNS ._SENT In_IN this_DT study_NN we_PP therefore_RB used_VBD primers_NNS that_WDT were_VBD designed_VBN for_IN genotype_NN 1_CD and_CC which_WDT were_VBD shown_VBN to_TO amplify_VB HCV_NP strains_NNS of_IN genotype_NN 1a_NP and_CC 1b_NP ._SENT Generalization_NN of_IN the_DT method_NN will_MD require_VB the_DT design_NN of_IN primers_NNS specific_JJ for_IN each_DT genotype_NN ._SENT These_DT different_JJ sets_NNS of_IN primers_NNS might_MD conceivably_RB be_VB used_VBN simultaneously_RB in_IN a_DT multiplex_JJ PCR_NP to_TO allow_VB amplification_NN of_IN any_DT HCV_NP genotype_NN present_NN in_IN the_DT patient_JJ sample_NN in_IN a_DT single_JJ reaction_NN ._SENT Alternatively_RB ,_, it_PP might_MD be_VB preferable_JJ to_TO keep_VB the_DT reactions_NNS separated_VBN :_: in_IN cases_NNS of_IN infection_NN by_IN more_JJR than_IN one_CD genotype_NN it_PP would_MD allow_VB for_IN monitoring_VBG the_DT evolution_NN of_IN HCV_NP quasispecies_NNS for_IN each_DT genotype_NN separately_RB ._SENT We_PP have_VBP designed_VBN our_PP$ primer_NN pairs_NNS with_IN the_DT capacity_NN to_TO do_VB nested_VBN PCR_NP for_IN increased_VBN sensitivity_NN ,_, but_CC of_IN course_NN when_WRB working_VBG with_IN high_JJ titer_NN samples_NNS (_( or_CC from_IN plasmids_NNS )_) one_CD round_NN of_IN PCR_NP with_IN the_DT inner_JJ pair_NN may_MD suffice_VB ._SENT Purification_NN of_IN the_DT synthesized_VBN peptides_NNS was_VBD achieved_VBN through_IN the_DT incorporation_NN of_IN the_DT Flag_NP tag_NN ._SENT Since_IN the_DT M2_NP monoclonal_NN antibody_NN can_MD in_IN principle_NN bind_NN to_TO the_DT Flag_NP sequence_NN at_IN either_CC the_DT N_NP or_CC C_NP terminus_NN ,_, the_DT exact_JJ location_NN did_VBD not_RB seem_VB to_TO matter_NN and_CC our_PP$ initial_JJ design_NN was_VBD to_TO put_VB the_DT Flag_NP at_IN the_DT C_NP terminus_NN ._SENT Experiments_NNS with_IN a_DT synthetic_JJ H-77_JJ peptide_NN confirmed_VBD that_IN purification_NN was_VBD achieved_VBN with_IN our_PP$ method_NN ,_, and_CC no_DT cleavage_NN of_IN the_DT peptide_NN could_MD be_VB observed_VBN after_IN prolonged_JJ incubation_NN in_IN the_DT reticulocyte_NN lysate_NN ._SENT However_RB ,_, with_IN translation_NN from_IN an_DT amplicon_NN we_PP did_VBD consistently_RB observe_VB a_DT cleavage_NN ,_, suggesting_VBG that_IN the_DT nascent_JJ peptide_NN ,_, as_IN it_PP was_VBD being_VBG synthesized_VBN ,_, was_VBD exposed_VBN to_TO proteases_NNS ._SENT In_IN hindsight_NN this_DT is_VBZ not_RB so_RB surprising_JJ ,_, since_IN in_IN order_NN to_TO bracket_VB the_DT HVR1_NP the_DT amplicon_NN must_MD contain_VB the_DT segment_NN coding_VBG for_IN the_DT C_NP terminus_NN of_IN the_DT E1_JJ glycoprotein_NN ,_, which_WDT is_VBZ highly_RB hydrophobic_JJ and_CC provides_VBZ a_DT transmembrane_JJ anchor_NN to_TO the_DT protein_NN ,_, causing_VBG retention_NN of_IN E1_NP in_IN the_DT endoplasmic_JJ reticulum_NN rather_RB than_IN channeling_VBG to_TO the_DT Golgi_NP ._SENT Presumably_RB ,_, the_DT highly_RB hydrophobic_JJ character_NN of_IN the_DT amino_NN terminus_NN of_IN this_DT peptide_NN results_NNS in_IN its_PP$ targeting_VBG by_IN the_DT proteasome_NN ,_, which_WDT preferentially_RB recognizes_VBZ exposed_JJ hydrophobic_JJ amino_NN acid_NN R_NN groups_NNS ._SENT With_IN the_DT hydrophilic_JJ Flag_NP tag_NN on_IN both_DT ends_NNS ,_, the_DT peptide_NN is_VBZ apparently_RB not_RB exposed_VBN to_TO protease_NN activity_NN ,_, perhaps_RB because_IN the_DT hydrophobic_JJ character_NN of_IN the_DT amino_NN terminus_NN is_VBZ altered_VBN by_IN the_DT highly_RB charged_VBN residues_NNS of_IN the_DT Flag_NP tag_NN ._SENT We_PP have_VBP ,_, however_RB ,_, no_DT good_JJ explanation_NN for_IN the_DT poor_JJ results_NNS obtained_VBD when_WRB the_DT Flag_NP tag_NN appeared_VBD only_RB at_IN the_DT N_NP terminus_NN ._SENT Using_VBG the_DT HCFLAG-3_NP and_CC HCFLAG-4_NP primers_NNS ,_, which_WDT direct_VBP the_DT synthesis_NN of_IN the_DT Flag_NP tag_NN on_IN both_DT ends_NNS ,_, we_PP consistently_RB obtained_VBD good_JJ results_NNS and_CC obtained_VBN peptides_NNS whose_WP$ masses_NNS were_VBD essentially_RB those_DT predicted_VBN for_IN clone_NN pCV-H77C_NN and_CC for_IN clone_NN pCV-J4L6S_NNS (_( not_RB shown_VBN )_) ._SENT In_IN addition_NN ,_, correct_JJ masses_NNS were_VBD observed_VBN for_IN a_DT mix_NN of_IN amplicons_NNS obtained_VBN from_IN these_DT two_CD clones_NNS (_( not_RB shown_VBN )_) and_CC three_CD main_JJ peptide_NN species_NNS after_IN translation_NN of_IN the_DT amplicon_NN from_IN the_DT H-77_JJ serum_NN (_( not_RB shown_VBN )_) ._SENT In_IN these_DT experiments_NNS we_PP did_VBD observe_VB a_DT consistent_JJ shift_NN from_IN the_DT predicted_VBN mass_NN which_WDT coincided_VBD with_IN the_DT predicted_VBN increase_NN of_IN 42_CD Da_NP caused_VBN by_IN N-terminal_JJ acetylation_NN ._SENT This_DT is_VBZ not_RB a_DT problem_NN ,_, since_IN in_IN all_PDT our_PP$ experiment_NN this_DT enzyme_NN mediated_VBD posttranslational_JJ modification_NN was_VBD consistent_JJ and_CC complete_JJ ._SENT More_RBR problematic_JJ for_IN our_PP$ purpose_NN was_VBD the_DT frequently_RB observed_VBN second_JJ peak_NN shifted_VBN by_IN approximately_RB 16_CD Da_NP ,_, which_WDT we_PP attributed_VBD to_TO incomplete_JJ and_CC inconsistent_JJ methionine_NN oxidation_NN ,_, a_DT common_JJ chemical_NN modification_NN ._SENT To_TO overcome_VB this_DT difficulty_NN we_PP redesigned_VBD the_DT sense_NN primer_NN to_TO direct_VB the_DT incorporation_NN of_IN an_DT alanine_NN between_IN the_DT methionine_NN and_CC the_DT Flag_NP tag_NN ._SENT As_RB predicted_VBN previously_RB ,_, this_DT resulted_VBN in_IN a_DT posttranslational_JJ cleavage_NN of_IN the_DT methionine_NN followed_VBN by_IN N_NP terminal_NN acetylation_NN ._SENT We_PP did_VBD not_RB observe_VB the_DT 16_CD Da_NP shifted_VBD second_JJ peaks_NNS when_WRB using_VBG this_DT primer_NN ._SENT Experiments_NNS with_IN clones_NNS pCV-H77C_NN and_CC pCV-J4L6S_NNS yielded_VBD peptides_NNS of_IN expected_VBN masses_NNS ,_, alone_RB or_CC in_IN combination_NN ._SENT Finally_RB ,_, mass_JJ spectrometry_NN measurements_NNS from_IN the_DT translated_VBN amplicon_NN obtained_VBN from_IN the_DT serum_NN aliquot_NN of_IN H-77_JJ yielded_VBN at_IN least_JJS three_CD distinct_JJ species_NNS whose_WP$ masses_NNS correspond_VBP favorably_RB to_TO those_DT predicted_VBN from_IN the_DT sequence_NN of_IN the_DT most_RBS frequent_JJ clones_NNS in_IN the_DT H-77_JJ quasispecies_NNS :_: 7,102_CD Da_NP for_IN the_DT master_NN clone_NN (_( present_JJ at_IN a_DT frequency_NN of_IN 70_CD per_IN 104_CD clones_NNS )_) ,_, 7,122_CD for_IN the_DT second_JJ most_RBS common_JJ clone_NN (_( with_IN a_DT frequency_NN of_IN 6_CD per_IN 104_CD clones_NNS )_) ,_, and_CC 7,056_CD for_IN the_DT third_JJ most_RBS common_JJ clone_NN (_( with_IN a_DT frequency_NN of_IN 5_CD per_IN 104_CD clones_NNS )_) ,_, the_DT other_JJ 16_CD clones_NNS identified_VBN being_VBG present_JJ at_IN frequencies_NNS of_IN 4_CD per_IN 104_CD clones_NNS or_CC less_JJR ._SENT Thus_RB ,_, our_PP$ procedure_NN appears_VBZ to_TO give_VB as_IN much_JJ information_NN as_IN sequencing_VBG approximately_RB 20_CD clones_NNS ,_, since_IN it_PP detected_VBD the_DT subspecies_NN present_NN at_IN roughly_RB 1_CD in_IN 20_CD (_( mass_NN ,_, 7,056_NP Da_NP )_) ._SENT The_DT MALDI-TOF-based_JJ assay_NN was_VBD applied_VBN to_TO serial_JJ samples_NNS from_IN two_CD patients_NNS monitored_VBN for_IN chronic_JJ hepatitis_NP C_NP at_IN our_PP$ institution_NN ._SENT The_DT first_JJ patient_NN presented_VBD initially_RB with_IN elevated_JJ ALT_NNS ,_, a_DT marker_NN of_IN liver_NN inflammation_NN that_WDT is_VBZ a_DT correlate_NN of_IN immune_JJ response_NN against_IN HCV_NP ._SENT In_IN a_DT follow-up_NN sample_NN obtained_VBD 6_CD months_NNS later_RBR ,_, the_DT quasispecies_NNS population_NN had_VBD completely_RB changed_VBN ,_, in_IN all_DT likelihood_NN because_IN of_IN effective_JJ immune_JJ selection_NN against_IN the_DT initial_JJ HCV_NP variants_NNS ._SENT Numerous_JJ studies_NNS have_VBP documented_VBN the_DT role_NN of_IN immune_JJ selection_NN in_IN the_DT evolution_NN of_IN HCV_NP quasispecies_NNS in_IN HVR1_NP ,_, including_VBG the_DT lack_NN of_IN evolution_NN in_IN patients_NNS with_IN agammaglobulinemia_NNS (_( reviewed_VBN in_IN reference_NN )_) ._SENT It_PP is_VBZ interesting_JJ that_IN at_IN the_DT time_NN when_WRB the_DT second_JJ sample_NN was_VBD taken_VBN ,_, the_DT ALT_JJ level_NN was_VBD normal_JJ ._SENT One_PP may_MD speculate_VB that_IN an_DT immune_JJ response_NN against_IN the_DT new_JJ variants_NNS had_VBD not_RB yet_RB been_VBN mounted_VBN ._SENT The_DT second_JJ patient_NN displayed_VBD a_DT very_RB homogeneous_JJ population_NN ,_, since_IN only_RB one_CD HCV_NP variant_NN could_MD be_VB demonstrated_VBN ._SENT It_PP is_VBZ possible_JJ that_IN this_DT homogeneity_NN is_VBZ a_DT consequence_NN of_IN the_DT infection_NN being_VBG acquired_VBN vertically_RB ,_, since_IN in_IN these_DT cases_NNS the_DT HCV_NP population_NN in_IN the_DT infant_NN is_VBZ usually_RB very_RB homogeneous_JJ ._SENT This_DT patient_NN also_RB presented_VBN with_IN elevated_JJ ALT_NNS ._SENT However_RB ,_, in_IN this_DT patient_NN the_DT immune_JJ response_NN failed_VBD to_TO eradicate_VB the_DT HCV_NP variant_NN ,_, since_IN 6_CD months_NNS later_RBR the_DT quasispecies_NN had_VBD exactly_RB the_DT same_JJ profile_NN ;_: at_IN that_DT time_NN ,_, the_DT ALT_JJ level_NN remained_VBD elevated_JJ ._SENT Currently_RB ,_, the_DT significance_NN of_IN decreased_VBN quasispecies_NNS diversity_NN at_IN the_DT amino_NN acid_NN level_NN at_IN the_DT time_NN of_IN seroconversion_NN has_VBZ been_VBN demonstrated_VBN ._SENT One_PP would_MD have_VB expected_VBN also_RB that_IN since_IN part_NN of_IN the_DT anti-HCV_NP activity_NN of_IN alpha_NN interferon_NN is_VBZ immune_NN mediated_VBN ,_, diversity_NN decreases_NNS should_MD be_VB predictive_JJ of_IN treatment_NN outcomes_NNS ._SENT This_DT has_VBZ in_IN fact_NN been_VBN recently_RB demonstrated_VBN ._SENT At_IN this_DT point_NN in_IN time_NN it_PP remains_VBZ unproven_JJ whether_IN quasispecies_JJ diversity_NN monitoring_NN will_MD also_RB be_VB of_IN benefit_NN in_IN longitudinal_JJ follow-up_NN of_IN patients_NNS ._SENT However_RB ,_, the_DT two_CD examples_NNS presented_VBN in_IN this_DT study_NN appear_VBP similar_JJ to_TO a_DT recent_JJ report_NN by_IN Curran_NP and_CC coworkers_NNS ,_, in_IN which_WDT patients_NNS with_IN mild_JJ disease_NN had_VBD an_DT HCV_NP population_NN whose_WP$ amino_NN acid_NN sequences_NNS in_IN HVR1_NP changed_VBD over_IN time_NN ,_, whereas_IN patients_NNS with_IN more_JJR severe_JJ illness_NN had_VBD static_JJ HCV_NP populations_NNS ._SENT Although_IN further_JJR work_NN will_MD be_VB required_VBN on_IN this_DT point_NN ,_, it_PP is_VBZ clear_JJ that_IN the_DT MALDI-TOF_NP assay_NN allows_VBZ for_IN the_DT monitoring_NN of_IN HCV_NP quasispecies_NNS in_IN the_DT clinical_JJ setting_NN in_IN a_DT meaningful_JJ way_NN ,_, and_CC is_VBZ expected_VBN to_TO contribute_VB to_TO a_DT better_JJR understanding_NN of_IN the_DT natural_JJ history_NN of_IN the_DT disease_NN ._SENT In_IN summary_NN we_PP have_VBP developed_VBN and_CC streamlined_VBN a_DT procedure_NN based_VBN on_IN MALDI-TOF_NP mass_JJ spectrometry_NN for_IN the_DT characterization_NN of_IN HCV_NP quasispecies_NNS in_IN HVR1_NP ._SENT This_DT assay_NN is_VBZ technically_RB less_RBR demanding_VBG to_TO perform_VB than_IN cloning_VBG and_CC sequencing_VBG many_JJ clones_NNS ,_, since_IN in_IN its_PP$ current_JJ state_NN it_PP involves_VBZ the_DT translation_NN of_IN the_DT (_( unpurified_JJ )_) amplicon_NN using_VBG a_DT commercially_RB available_JJ kit_NN ,_, the_DT purification_NN of_IN the_DT peptide_NN mix_NN using_VBG a_DT simple_JJ and_CC rapid_JJ method_NN ,_, and_CC the_DT submission_NN to_TO MALDI-TOF_NP analysis_NN ._SENT The_DT procedure_NN described_VBN here_RB could_MD also_RB be_VB easily_RB adapted_VBN to_TO other_JJ chronic_JJ viral_JJ infections_NNS in_IN which_WDT quasispecies_NNS play_VBP a_DT role_NN ,_, for_IN example_NN the_DT quasispecies_NNS observed_VBD in_IN the_DT V3_NP loop_NN of_IN the_DT gp120_JJ surface_NN glycoprotein_NN of_IN human_JJ immunodeficiency_NN virus_NN ._SENT 